Association of sTREM-1 and Neutrophil-to-Lymphocyte Ratio as Prognostic Markers in COVID-19 Short- and Long-Term Mortality

Turgunova L. Mekhantseva I. Akhmaltdinova L. Zhumadilova Z. Turmukhambetova A. Kostinov M.
2023 Dove Medical Press Ltd

Journal of Inflammation Research
2023 #16 5807 - 5817 pp.

Aim: Current problem related to COVID-19 is various complications after disease, especially long-term mortality after COVID-19. Routine blood tests presented their effectiveness in the diagnosis, prognosis and mortality of COVID-19. The neutrophil-tolymphocyte ratio (NLR) is an important marker of systemic inflammation. Soluble Trigger receptor expressed on myeloid cells-1 (sTREM-1) is considered an intrinsic enhancer of inflammatory signals. This study examined the predictive value of these markers in COVID-19 mortality. Methods: A prospective study was conducted involving patients with COVID-19 in Karaganda, Kazakhstan. The neutrophil–tolymphocyte ratio (NLR) was calculated as the absolute number of neutrophils divided by the absolute number of lymphocytes. The level of sTREM-1 in the blood serum was evaluated by ELISA. Results: Plasma sTREM-1 concentration greater than 59.08 pg/mL and an NLR greater than 2.29 had an increased risk of early mortality (hazard ratio = 8.07; 95% CI: 1.03–62.17 and 9.24; 95% CI: 1.202–71.08, respectively); for long-term mortality of sTREM-1 greater than 47.34 pg/mL (hazard ratio = 7.96; 95% CI: 1.072–59.18) and NLR greater than 2.10 (hazard ratio = 11.52; 95% CI: 1.551–85.52). Conclusion: This study suggests that early levels of sTREM-1 and NLR are associated with the risk of 6-month mortality after experiencing COVID-19.

COVID-19 , mortality , neutrophil-to-lymphocyte ratio , prognostic markers , sTREM-1

Text of the article Перейти на текст статьи

Karaganda Medical University, Department of Internal Medicine, Karaganda, Kazakhstan
I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russian Federation
Sechenov First Moscow State Medical University, Department of Epidemiology and Modern Vaccination Technologies, Moscow, Russian Federation

Karaganda Medical University
I.I. Mechnikov Research Institute of Vaccines and Sera
Sechenov First Moscow State Medical University

10 лет помогаем публиковать статьи Международный издатель

Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026